Last reviewed · How we verify
SHR8028 eye drops
SHR8028 is a selective rho-associated protein kinase (ROCK) inhibitor administered as eye drops to reduce intraocular pressure in glaucoma.
SHR8028 is a selective rho-associated protein kinase (ROCK) inhibitor administered as eye drops to reduce intraocular pressure in glaucoma. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | SHR8028 eye drops |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | ROCK inhibitor |
| Target | ROCK (Rho-associated coiled-coil-containing protein kinase) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ROCK inhibitors decrease intraocular pressure by promoting aqueous humor outflow through the trabecular meshwork and Schlemm's canal, and by reducing aqueous humor production. SHR8028 is formulated as topical eye drops to achieve local ocular delivery while minimizing systemic exposure.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Ocular discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR8028 eye drops CI brief — competitive landscape report
- SHR8028 eye drops updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI